China NMPA Drug Inspection - Xiuzheng Pharmaceutical Group Co., Ltd. - Isatis root granules

On December 20, 2017, the Shandong Provincial Food and Drug Administration, operating within the National Medical Products Administration (NMPA) framework, announced significant quality control failures involving multiple pharmaceutical companies. During recent sampling inspections, six batches of drugs from various manufacturers were found to be substandard. The implicated companies include Shijiazhuang Northern Pharmaceutical Co., Ltd., Furen Pharmaceutical Group Co., Ltd., Jiangsu Dahongying Hengshun Pharmaceutical Co., Ltd., Haikou Qili Pharmaceutical Co., Ltd., Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. Baiyunshan Hejigong Pharmaceutical Factory, and Suzhou Yushi Pharmaceutical Co., Ltd. The primary violations involved critical quality attributes, specifically "characteristic chromatograms and inspection items," which indicate the drugs did not meet required quality standards. In response, municipal food and drug administrations have implemented control measures, including sealing, seizing, suspending sales, and recalling the affected products. Investigations and prosecutions have been initiated against the responsible manufacturers and sampled units. Moving forward, authorities mandate enhanced supervision of these products and enterprises, requiring them to investigate root causes, formulate and execute rectification measures, and effectively eliminate potential risks to public health and safety.